1. , . Skin as an organ of protection. In: , , , , , , eds. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York, NY: McGraw-Hill; 2008;383–395.
2. , , , . Electroporations of mammalian skin: a mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci USA. 1993;90:10504–10508.
3. . Transdermal drug delivery: past, present, future. Mol Interven. 2004;4:308–332.
4. , , . Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet. 200:38–59.
5. , , , , , . The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetcs and pharmacodynamic effects. Pain. 1989;37:193–202.
6. , , , , . The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems. Pain. 1990;40:21–28.
7. , , , . Postoperative analgesia with transdermal fentanyl following lower abdominal surgery. Anaesthesia. 1995;50:300–303.
8. , , , , . Plasma fentanyl concentrations during transdermal delivery of fentanyl to surgical patients. Br J Anaesth. 1988;60:614–618.
9. , , . Clinical pharamacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet. 200:38:59–89.
10. , . Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery. Br J Anaesth. 1988;60:608–613.
11. , , , , . Absorption characteristics of transdermally administered fentanyl. Anesthesiology. 1989;70:928–934.
12. , . A review of the use of fentanyl in analgesia in management of acute pain in adults. Anesthesiology. 1999;90:576–599.
13. , , . Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket. Anesth Analg. 2001;93;647–648.
14. . Fentanyl transdermal system approved for chronic pain. JAMA. 1990;264:1802.
15. , , , . Lidocaine patch: double-blinded controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65:39–44.
16.Lidoderm (lidocaine patch 5%) [package insert]. Chadds Ford, PA: Endo Pharmaceuticals; 2006.
17. , , , . Topical lidocaine patch 5% relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enrichment enrollment study. Pain. 1999;80:533–538.
18. , , , and the . Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. Pain Med. 2002;3:324–332.
19. , , . Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain. 2003;106;151–158.
20. , , , , . A comparison of lidocaine patch 5% vs naproxen 500 mg twice weekly for the relief of pain associated with carpal tunnel syndrome: a 6-week, randomized, parallel-group study. Medscape Gen Med. 2006;8:33.
21. , . Management of complex regional pain syndrome type II using lidoderm 5% patches. Br J Anesth. 2007;98:261–262.
22. , , , . Use of lidocaine patch 5% for chronic low back pain; a report of four cases. Pain Med. 2002;3:361–365.
23. . 5% lidocaine patch in the treatment of neuropathic pain of diverse origin. [abstract]. Eur J Pall Care-Abstract book 9 Congress of the European Association for Palliative Care. 2003;80.
24. , . Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. Clin J Pain. 200:16(3):205–208.
25. . . The 5% lidocaine patch reduces pain intensity in professional athletes with sports injury pain without significant systemic effects or cognitive and performance impairment. Arch Phys Med Rehab. 2005;86.e34.
26. , . Pharmacokinectics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother. 2002;236–240.
27. , , . Effectiveness of lidocaine patch 5% in diabetic neuropathy patients with or without allodynia (2003) Abstract presented at: the 7th International Conference on the Mechanisms and Treatment of Neuropathic Pain; September 18–20; San Francisco, CA.
28. , , , . , . Lidocaine patch 5% in patients with acute/subacute chronic low back pain: Impact on pain intensity, pain relief, and pain interference with QOL (2003) Abstract presented at: the 22nd Annual Meeting of the American Pain Society; March 20–23; Chicago, IL.
29. . More than 7 years of consistent neuropathic pain relief in geriatric patients. Arch Intern Med. 2003;163:628.
30.Flector (diclofenac epolamine topical patch 1.3%), [package insert]. Sanbonmatsu, Kagawa, Japan: Teikoku Seiyaki Co, Ltd; 2007.
31. , , , , . Topical diclofenac patch relieves minor sports injury pain: results of a multicenter controlled clinical trial. J Pain Symptom Manage. 2000;19:287–294.
32. , , . Diclofenac patch for topical treatment of acute impact injuries: a randomised, double blinded, placebo controlled, mutlicenre study. Br J Sports Med. 2004;38:318–323.
33. , , , . Transdermal diclofenac patch vs eutectic mixture of local anesthestics for venous cannulation pain. Can J Anesth. 2007;54:196–200.
34. , , . Transdermal fentanyl system plus im ketorolac for the treatment of postoperative pain. Can J Anaesth. 1997;44377–44384.
35. , , . Postoperative pain control with a new transermal fentanyl delivery system: a multicenter trial. Anesthesiology. 1995;83:470–477.
36. , , . Biopharmaceutics of a new transdermal fenanyl device. Anesthesiology. 1995;83:459–469.
37. , , . Bioconversion of Naltrexone and Its 3-O-Alkyl-Ester Prodrugs in a Human Skin Equivalent. J Pharm Sci 2005;94:828–836.
38. , . Iontophoresis: the process behind noninvasive drug delivery. Reg Anesth Pain Med. 2005;30:292–294.
39. , , , . Transdermal iontophoresis. Drug Deliv. 2007.
40. , , . Non-invasive assessment of the effects of iontophoresis on human skin in-vivo. J Pharm Pharmacol. 2001;52:769–777.
41.Ionsys (fentanyl iontophoretic transdermal system) [package insert]. Raritan NJ: Ortho-McNeil, Inc; August 2006.
42. . Fentanyl Iontophoretic Transdermal System: A Review. Techniques in Regional Anesthesia and Pain Management. 2007;11(1):3–8.
43. , , , . Effect of current density on pharmacokinetics following continuous or intermittent input from a fentanyl electrotransport system. J Pharm Sci. 1998;87:976–981.
44. , , , , , . Fentanyl delivery from a electrotransport system. Delivery is a function of total current, not duration of current. J Clin Pharmacol. 1998;48:951–958.
45. , , , , . Reproducible fentanyl doses delivered intermittently at different time intervals from an electrotransport system. J Pharm Sci. 1999;88:835–841.
46. , , , . Characterisation of the pharmacokinetics of fentanyl HCL patient-controlled transdermal system (PTCS): effect of current magnitude and multiple-day dosing, and comparison with IV fentanyl administration. Clin Pharmacokinet. 2005;44(suppl 1):7–15.
47. , , . Postoperative analgesic effects of three demand dose sizes of fentanyl administered via patent controlled analgesia. Anesth Analg. 1998;87:890–895.
48. , , , . Effects of application site and subject-controlled demographics on the pharmacokinetics of fentanyl HCL patient-controlled transdermal system (PCTS). Clin Pharmacokinet. 2005;44:25–32.
49. , , , . The effect of dosing frequency on the pharmacokinetics of a fentanyl HCL patient-controlled transdermal system (PCTS). Clin Pharmacokinet. 2005;44:17–24.
50. , , , , . System-related events and analgesic gaps during postoperative pain management with the fentanyl iontophoretic transdermal system and morphine intravenous patient-controlled analgesia. Anesth Analg. 2007;105:1437–1441.
51. , , . Improving patient and nurse outcomes: a comparison of nurse tasks and time associated with two patient-controlled analgesia modalities using Delphi panels. Pain Manage Nurs. 2007;8:86–95.
52. , , , , , . Fentanyl iontophoretic transdermal system for acute-pain management after orthopedic surgery : a comparative study with morphine intravenous patient-controlled analgesia. Reg Anesth Pain Med. 2006;31(6):546–554.
53. , , , . The safety and efficacy of a fentanyl patient-controlled transdermal system for acute postoperative analgesia: a multicenter, placebo-controlled trial. Anesth Analg. 2004;98:427–433.
54. . Postoperative pain management with a patient-controlled transdermal delivery system for fentanyl. Am J Health-Syst Pharm. 2005;62:1171–1176.
55. , , , , . Iontophoretic fentanyl patient-activated analgesic delivery system for post-operative pain: a double-blind, placebo-controlled trial. Anesth Analg. 2006;102:188–194.
56. , , , , . Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: a randomized controlled trial. JAMA. 2004;291:1333–1341.
57. , , , , , . Efficacy and safety of the fentanyl iontophoretic transdermal (ITS) and intravenous patient-controlled analgesia (IV PCA) with morphine for pain management following abdominal or pelvic surgery. Pain Med. 2007;8(8):657–668.
58. , , , , . The safety and efficacy of fentanyl iontophoretic transdermal system compared with morphine intravenous patient-controlled analgesia for post-operative pain management: an analysis of pooled data from three randomized, active-controlled clinical studies. Anesth Analg. 2007;105:1428–1436.
59.Lidosite Topical System [package insert. Fairlawn NJ: Vyteris Inc; 2004.
60. , , , , . Efficacy of postoperative epidural analgesia: a meta-analysis. JAMA. 2003;290:2456–2463.
61. , , . Efficacy of postoperative patient-controlled and continuous infusion epidural analgesia versus intravenous patient-controlled analgesia with opioids: a meta-analysis. Anesthesiology. 2005;103:1079–1088.
62. . Acute pain: lessons learned from 25,000 patients. Reg Anesth Pain Med. 1999;24:499–505.
63. , , , . Sustained-release morphine for epidural analgesia in rats. Anesthesiology. 1996;85:331–338.
64. , , , . Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. Anesthesiology. 1999;90:1402–1412.
65. , , , , . Single-dose extended-release epidural morphine for pain following hip arthroplasty. Am J Therapeut. 2006;13:423–431.
66. , , , Forty-eight hours of post-operative pain relief after total hip arthroplasty with a novel, extended-release epidural morphine formulation. Anesthesiology. 2005;102:1014–1022.
67. , , , , . Evaluation of a single-dose extended-release epidural morphine formulation for pain after knee athroplasty. J Bone Joint Surg. 2006;88A:271–281.
68. , , ., , for the . A comparison of DepoDur,™ a novel, single-dose extended-release epidural morphine, with a standard epidural morphine for pain relief after lower abdominal surgery. Anesth Analg. 2005;100:1065–1074.
69. , , , for the . Single-dose, sustained-release epidural morphine in the management of postoperative pain after elective cesarean section: results of a multicenter randomized controlled study. Anesth Analg. 2005;100:1150–1158.
70.[package insert]. San Diego CA: SkyePharma Inc; 2007.
71. , . Pharmacology of drugs formulated with Depofoam™: a sustained release drug delivery system for parenteral administration using mutlivesicular liposome technology. Clin Pharmacokinet. 2006;45:1153–1176.
72. , , . Acute post-surgical pain management: a critical appraisal of current practice, December 2–4, 2005. Reg Anesth Pain Med. 2006;31(4 suppl 1):1–42.